Intravascular stent endothelialization. A goal worth pursuing?

D. Schneider,D. Dichek

DOI: https://doi.org/10.1161/01.CIR.95.2.308

IF: 37.8

1997-01-21

Circulation

Abstract:The explosive growth of interventional cardiology has been accompanied by a proliferation of devices designed both to eliminate coronary stenoses and to prevent their recurrence. The intravascular stent is certainly one of the most successful of these devices. First deployed in humans in 19861 and approved by the FDA in 1993, an estimated 100 000 intracoronary stents per year are deployed in the United States (personal communication, Martin B. Leon, MD, Washington Hospital Center, Washington, DC). No interventional facility in 1996 can be without the capability for stent deployment. Stents are useful both for acute closure and for improving the long-term success of balloon angioplasty. In selected populations, stent deployment decreases the rate of restenosis after coronary angioplasty, as demonstrated by the STRESS2 and Benestent3 trials. Despite their utility, intracoronary stents have been plagued by two problems during their development: acute occlusion due to thrombosis and the persistent occurrence of restenosis. Initial reports of intracoronary stent deployment in humans noted stent-related thrombosis rates of 3% to 4% under elective conditions,2 3 rising to 8% to 16% in bailout or emergency situations.4 These unacceptably high rates were initially combated with aggressive drug therapy, including both anticoagulant and antiplatelet agents. This therapy decreased stent thrombosis but did so at a cost of additional hours of patient care as well as increased vascular and bleeding complications, leading to longer hospital stays and higher hospital bills.2 3 In-stent restenosis remains a significant clinical problem, with rates of 13% even in the more optimistic studies.5 More progress has been made in combating stent thrombosis than in decreasing the rate of in-stent restenosis. Colombo et al6 found that if stents were appropriately deployed, thrombosis rates of <1% could be achieved with antiplatelet therapy alone. Scho¨mig et al7 reported …